Sarcopenia--consequences, mechanisms, and potential therapies.
about
Emerging drugs for sarcopenia: age-related muscle wastingTreatment with a corticotrophin releasing factor 2 receptor agonist modulates skeletal muscle mass and force production in aged and chronically ill animalsSarcopaenia and rheumatoid arthritis.Influence of exercise intensity in older persons with unchanged habitual nutritional intake: skeletal muscle and endocrine adaptations.Endurance exercise and conjugated linoleic acid (CLA) supplementation up-regulate CYP17A1 and stimulate testosterone biosynthesisCatechol-o-methyltransferase gene polymorphism is associated with skeletal muscle properties in older women alone and together with physical activity.Emergent cardiovascular risk factors in the very elderly.Sarcopenia: etiology, clinical consequences, intervention, and assessment.Exercise restores muscle stem cell mobilization, regenerative capacity and muscle metabolic alterations via adiponectin/AdipoR1 activation in SAMP10 micePower training and postmenopausal hormone therapy affect transcriptional control of specific co-regulated gene clusters in skeletal muscle.Studies of complex biological systems with applications to molecular medicine: the need to integrate transcriptomic and proteomic approaches.Impact of lifelong sedentary behavior on mitochondrial function of mice skeletal muscle.Sarcopenia is prevalent in patients with Crohn's disease in clinical remission.Tea catechin ingestion combined with habitual exercise suppresses the aging-associated decline in physical performance in senescence-accelerated mice.Cardiorespiratory fitness and body composition in postmenopausal women.Target population for clinical trials on sarcopenia.Identification of novel genes involved in sarcopenia through RNAi screening in Caenorhabditis elegansThe aromatic amino acid tryptophan stimulates skeletal muscle IGF1/p70s6k/mTor signaling in vivo and the expression of myogenic genes in vitro.Low level laser therapy associated with a strength training program on muscle performance in elderly women: a randomized double blind control study.Pulmonary rehabilitation in chronic obstructive pulmonary disease.The Impacts of ACE Activity according to ACE I/D Polymorphisms on Muscular Functions of People Aged 65Is quadriceps muscle strength a determinant of the physical function of the elderly?Tongue thickness relates to nutritional status in the elderly.Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old miceSkeletal muscle mass is associated with bone geometry and microstructure and serum insulin-like growth factor binding protein-2 levels in adult women and men.Dihydrotestosterone treatment rescues the decline in protein synthesis as a result of sarcopenia in isolated mouse skeletal muscle fibres.Denervation induces cytosolic phospholipase A2-mediated fatty acid hydroperoxide generation by muscle mitochondriaIdentification of biological markers for better characterization of older subjects with physical frailty and sarcopenia.The adipokine leptin increases skeletal muscle mass and significantly alters skeletal muscle miRNA expression profile in aged miceThe potential benefits of creatine and conjugated linoleic acid as adjuncts to resistance training in older adults.Role of muscle-derived growth factors in bone formationExercise-induced alterations in intramyocellular lipids and insulin resistance: the athlete's paradox revisitedLongitudinal decline of neuromuscular activation and power in healthy older adults.The association between dehydroepiandosterone and frailty in older men and women.Sarcopenia in women with rheumatoid arthritis.Inflammation: roles in aging and sarcopenia.Comparative proteomic analysis of the aging soleus and extensor digitorum longus rat muscles using TMT labeling and mass spectrometry.Mitochondrial DNA shifting in older adults following resistance exercise training.Ageing has no effect on the regulation of the ubiquitin proteasome-related genes and proteins following resistance exercise.Exercise and nutritional interventions for improving aging muscle health.
P2860
Q28295716-54E16185-E189-4C6E-9CD0-031529B1BF58Q28570699-A0FA511A-745E-4370-9859-8D9BD145E0DBQ30234376-BAFCFBFF-4A5C-4764-95F6-7CC3E3625787Q30475244-28CA7DB0-23AE-4E83-9C44-A872BB16733BQ31143786-21DDB31E-49E5-45BA-B3DF-6BD0970414F9Q33324397-2BFB8498-F41C-4004-B673-F9EC221E3BDFQ33354807-B644584D-2082-49EC-A426-9A7F8369A475Q33706637-9F8C39B2-4BD7-4FA9-9F15-CF1B062911B8Q33813584-D80BFDFE-E730-421C-9310-67C5E90D1D42Q34080414-8798B46F-49C8-467B-A792-2FADA58A78A3Q34239462-80A18F7B-048A-4844-85B3-F9F32E6BAD95Q34310382-8172C2F7-1868-4B2D-BCDF-76DD873E19A6Q34591955-05F0C461-F35E-4B7B-9FC0-F84F64BC4580Q34591989-8F2A4BFC-C1B1-474D-B462-911BE6BD22D3Q35094048-6B87665B-64D7-4A36-B761-1D1FE3EBE6FBQ35258802-7283FDA9-D4AF-484D-B1F6-32E0E577552DQ35678558-2DAB2FF7-3FC2-4CCE-8999-A4AB473D8581Q35733411-2898F036-4F5C-4A4F-BE87-6D0CAF62AB1BQ36036946-4D3F34F4-1E53-4988-8F71-46FFC3DCC484Q36075213-D163534F-EF97-4213-B09A-196C170C9442Q36223705-CB7136A6-F85B-4F7F-ADDD-7AA82D337E6DQ36342567-D8DB7220-2DFD-41A6-B07E-20AA146A35F7Q36484968-74E33AC6-932F-4535-890D-D99611E45948Q36646575-F8448A9E-AC76-41CA-9D3B-5A6F4650715FQ36820895-EE96AED3-6FED-4B30-8CFC-DB5631AF41F6Q36892343-46AE4F38-FCC3-4A4F-B4A2-A13B1E001FA0Q37029870-B1B58095-C26D-4A14-A71F-BB6AE63B0BCBQ37074556-F0103372-7A5E-4345-AB31-96B71FF1AB34Q37087216-2DBBEEE7-8C61-46E7-8735-4E43C037F1ABQ37112576-49FB87BE-F308-47C5-9ADB-B1FCD1072447Q37121913-2D3081AB-F2C4-4DE3-BD29-661E25341E84Q37246314-2098FEF3-97B3-4289-B404-4E016043690CQ37247684-A88030F7-EB40-4D99-8656-3E3B3E9A8389Q37288797-0944A0A6-4AF1-416F-982C-05C31CB1488EQ37305184-65044700-ADC0-48EA-81A2-98909290DE76Q37313766-060A9EDD-F015-4188-BC5C-254607DEF4A7Q37353851-BA9EE246-07D9-4CD6-AAC7-37C3EF2E28AFQ37485991-34D3219A-C12E-4DA4-8144-559009ADFBB0Q37535069-352BE70A-B169-4585-80C4-B87A740FFF3EQ38004953-4F38A43E-7B3B-4C12-86B5-E4606A675B33
P2860
Sarcopenia--consequences, mechanisms, and potential therapies.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Sarcopenia--consequences, mechanisms, and potential therapies.
@ast
Sarcopenia--consequences, mechanisms, and potential therapies.
@en
type
label
Sarcopenia--consequences, mechanisms, and potential therapies.
@ast
Sarcopenia--consequences, mechanisms, and potential therapies.
@en
prefLabel
Sarcopenia--consequences, mechanisms, and potential therapies.
@ast
Sarcopenia--consequences, mechanisms, and potential therapies.
@en
P1476
Sarcopenia--consequences, mechanisms, and potential therapies.
@en
P2093
P304
P356
10.1016/S0047-6374(02)00196-3
P577
2003-03-01T00:00:00Z